Public/private collaborative projects

Other projects
— Share on

Oncology, immunology, tumor models

OncoTrial

Development of cellular, tissular and animal models in oncology

After over 15 years of collaboration, the teams from the BIOSIT joint service unit (UMS) and the BIOTRIAL company have founded the OncoTrial joint laboratory (LabCom) for preclinical oncology research to understand and develop cancer models. The first cancers chosen (glioma, lung, breast, kidney, liver, skin and blood) are the ones for which Rennes has clinical, biological and research expertise and a collection of human and canine (CaniDNA) biological samples.

The growth of over 50 tumour cell lines (human/mouse) has been characterised in mice and the progress of these tumours can now be monitored using luminescence. A dedicated model of spontaneous liver cancer has also been established. These models allow the effectiveness of new therapies to be evaluated. The characterisation of recurring mutations between tumours in humans and dogs and the development of primary cultures also offer a screening model for therapies targeting mutations. The economic benefits for BIOTRIAL emerged in the second year. They involve the in vitro and in vivo models of glioblastomas and an in vivo bioluminescence model of lung cancer.

 

The project

ANR programme: LabCom

Edition, project duration: 2014, 54 months

ANR grant: € 400,000

Coordinator:

Project region: Bretagne

Main publication or contribution:

  • Fouqué et al. 2016
  • Ulvé et al. 2017

Partners:

  • INSERM and CNRS UMR at the Rennes site
  • The BIOTRIAL company
Représentation 3D d’une tumeur pulmonaire luminescente obtenue après injection caudale de la lignée tumorale.
3D imaging of a luminescent lung tumor obtained after the cell line injection into the mouse's tail. © Dr Ulrich Jarry UMS Biosit
perspectives
perspectives

The public-private partnership arising from this joint laboratory has led to the development of several beneficial models and approaches for cancer research in Rennes. BIOTRIAL signed its first industrial contracts in the second year of operation, with revenues rising steadily. The new developments and contracts have generated R&D activity at the BIOSIT UMS platforms. The fruitful collaboration is continuing.

Top